Associations of sphingosine-1-phosphate with soluble P-selectin and adverse clinical outcome in patients with cerebral ischemia with and without acetylsalicylic acid treatment
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-025-04595-w ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Nils-Ole Gloyer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: P-Selectin, Lysophospholipids, Aspirin, Sphingosine. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Hamburg-Eppendorf (UKE).
Abstract (Originalsprache)
Patients with overt cerebral ischemia are at risk for adverse events after hospital discharge. Sphingosine-1-phosphate is a potent lipid mediator produced and secreted by platelets, which is inhibited via acetylsalicylic acid (ASA). The associations of sphingosine-1-phosphate with biomarkers of platelet activation, i.e., thromboxane B 2 and soluble P-selectin, as well as with clinical outcome in ischemic stroke or transient ischemic attack patients’ subgroups with and without ASA has not yet been investigated. The bioMARKers in STROKE (MARK-STROKE) cohort is a prospective, single-center, observational study including adult patients with a diagnosis of ischemic stroke or transient ischemic attack. Sphingosine-1-phosphate, thromboxane B 2 , and soluble P-selectin were measured by liquid chromatography-tandem mass spectrometry and ELISA, respectively, to investigate cross-sectional and outcome associations in ASA medication groups. Overall, we included 374 patients (median age 70 (IQR 58; 78) years; sex 242 (64.7%) males; ASA, yes 270 (72.2%)). During the first 365 days of follow-up, we recorded 79 adverse events (death, stroke, myocardial infarction, rehospitalization) in 274 patients with available follow-up. While no statistical differences in neurological and functional deficits were determined by sphingosine-1-phosphate, thromboxane B 2 , and soluble P-selectin in both ASA medication groups, patients without ASA intake and high soluble P-selectin had shorter event-free survival times (high soluble P-selectin 250 (95%CI 205; 296) days; low soluble P-selectin 331 (95%CI 304; 358) days; p = 0.005). In addition, adjusted Cox-regression analysis revealed a higher hazard ratio (HR) for an adverse event during follow-up (HR = 3.22 (95%CI 1.41; 7.36); p = 0.005). Our findings may indicate the usability of soluble P-selectin in ASA-naive patients with ischemic stroke/transient ischemic attack for risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- German Center for Cardiovascular Research (DZHK e.V.) Partner Site, Hamburg/Kiel/Lübeck, Hamburg, Germany.
- Department of Pharmacology, University Medicine Greifswald, Greifswald, Germany.
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Pharmacology and Toxicology, University Medicine Oldenburg, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.
Förderung
- Universitätsklinikum Hamburg-Eppendorf (UKE)
Zitieren
APA
Gloyer, N. O., Moritz, E., Schwieren, L., Meyer, U., Thomalla, G., Daum, G., Magnus, T., Böger, R., Choe, C. U., Rauch, B. H., & Schwedhelm, E. (2026). Associations of sphingosine-1-phosphate with soluble P-selectin and adverse clinical outcome in patients with cerebral ischemia with and without acetylsalicylic acid treatment. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04595-w
Vancouver
Gloyer NO, Moritz E, Schwieren L, Meyer U, Thomalla G, Daum G, et al. Associations of sphingosine-1-phosphate with soluble P-selectin and adverse clinical outcome in patients with cerebral ischemia with and without acetylsalicylic acid treatment. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04595-w
BibTeX
@article{Gloyer2026,
author = {Gloyer, Nils-Ole and Moritz, Eileen and Schwieren, Laura and Meyer, Ulrike and Thomalla, Götz and Daum, Günter and Magnus, Tim and Böger, Rainer and Choe, Chi-Un and Rauch, Bernhard H and Schwedhelm, Edzard},
title = {Associations of sphingosine-1-phosphate with soluble P-selectin and adverse clinical outcome in patients with cerebral ischemia with and without acetylsalicylic acid treatment},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-025-04595-w}
}
EUVIMED